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INTRODUCTION 31
Platinum-based chemotherapy remains the stan-32 dard of care for patients with metastatic urothelial 33 carcinoma (UC) and good performance status; 34 however, most patients become platinum-refractory 35 and their subsequent management remains a chal-36 lenge. Prognosis is poor for these patients, with 37 overall response rates (ORRs) <20% and overall 38 survival (OS) ranging from 6-9 months with tax-39 ane or vinflunine single-agent chemotherapy [1] [2] [3] . 40 Five immune checkpoint inhibitors (ICIs) target-41 ing the programmed death-ligand 1/programmed Duration of response was longer on the ramucirumab 172 arm (median 4.9 mo; 95% CI = 3.9-6.7) than the 173 placebo arm (median 3.5 mo: 95% CI = 2.8--4.2) 174 (Table 3) . Tumor response in both arms was similar in 175 upper and lower UC. Four of the 5 responders on the 176 ramucirumab arm had a Bellmunt risk factors score 177 of 2 (Table 3) . Duration of treatment for each patient 178 on both treatment arms is summarized in Figure S2 (Table S1 ).
197
The median duration of therapy was 10.8 weeks (IQR Abbreviations: ICI = immune checkpoint inhibitor; IQR = interquartile range; mo = month; PD-1 = programmed death-1; PD-L1 = programmed death-ligand 1. (10) 1 1 / 4 (25) 1 / 11 (9.1) 2 4 / 12 (33.3) 0 / 6 (0) 3 0 / 0 (0) 0 / 1 (0) Abbreviations: CI = confidence interval; UC = urothelial carcinoma. a One of 17 patients on the ramucirumab arm and 1 among 28 on the placebo arm received no study treatment. b At the time of PFS datalock, one placebo arm patient was categorized as complete response at cycle 6. The next response assessment was in cycle 9 and this patient was recorded as a nontarget progressive disease. Per RECIST criteria, the overall response for this patient must therefore be a partial response rather than a complete response. c The UC of 2 patients on the placebo arm was denoted as "Other" rather than upper or lower. d The Bellmunt risk factors were Eastern Cooperative Oncology Group performance status > 0, presence of liver metastases. and haemoglobin < 10 g/dl. Fig. 1 . Waterfall plot depicting best percent change from baseline in tumor size and best overall tumor response for prior-ICI patients by RANGE treatment arm. The prior-ICI patient population is shown by RANGE treatment arm, ramucirumab/docetaxel (left) and placebo/docetaxel (right), with the graph depicting the best relative change in tumor size (%) and tumor response (see colour key). Patients on each treatment arm were assigned an identification number; the same patient numbers are reflected in Figure S2 , Supplemental Information. The chart below each Waterfall plot indicates the sites of metastases for each patient. Abbreviations: PD = progressive disease; PR = partial response; SD = stable disease. tion (Table 5 ; Table S2 , Supplementary Information). 
